Detalhe da pesquisa
1.
RNA-seq of newly diagnosed patients in the PADIMAC study leads to a bortezomib/lenalidomide decision signature.
Blood
; 132(20): 2154-2165, 2018 11 15.
Artigo
Inglês
| MEDLINE | ID: mdl-30181174
2.
International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease.
Blood
; 132(20): 2115-2124, 2018 11 15.
Artigo
Inglês
| MEDLINE | ID: mdl-30181172
3.
Symptoms and anxiety predict declining health-related quality of life in multiple myeloma: A prospective, multi-centre longitudinal study.
Palliat Med
; 33(5): 541-551, 2019 05.
Artigo
Inglês
| MEDLINE | ID: mdl-31060467
4.
Outcomes of relapse in patients with deferred autologous stem cell transplant after achieving at least very good partial response following bortezomib, adriamycin, dexamethasone chemotherapy for newly diagnosed multiple myeloma in the phase II PADIMAC trial.
Br J Haematol
; 196(4): e33-e37, 2022 02.
Artigo
Inglês
| MEDLINE | ID: mdl-34636043
5.
The management of Castleman disease.
Br J Haematol
; 195(3): 328-337, 2021 11.
Artigo
Inglês
| MEDLINE | ID: mdl-34340261
6.
The impact of disease-related symptoms and palliative care concerns on health-related quality of life in multiple myeloma: a multi-centre study.
BMC Cancer
; 16: 427, 2016 07 07.
Artigo
Inglês
| MEDLINE | ID: mdl-27387201
7.
Prevalence of symptoms in patients with multiple myeloma: a systematic review and meta-analysis.
Eur J Haematol
; 97(5): 416-429, 2016 Nov.
Artigo
Inglês
| MEDLINE | ID: mdl-27528496
8.
Improving the assessment of quality of life in the clinical care of myeloma patients: the development and validation of the Myeloma Patient Outcome Scale (MyPOS).
BMC Cancer
; 15: 280, 2015 Apr 14.
Artigo
Inglês
| MEDLINE | ID: mdl-25884627
9.
Understanding what matters most to people with multiple myeloma: a qualitative study of views on quality of life.
BMC Cancer
; 14: 496, 2014 Jul 09.
Artigo
Inglês
| MEDLINE | ID: mdl-25005145
10.
Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial.
Lancet Oncol
; 14(11): 1055-1066, 2013 Oct.
Artigo
Inglês
| MEDLINE | ID: mdl-24007748
11.
Fluorescence-based experimental model to evaluate the concomitant effect of drugs on the tumour microenvironment and cancer cells.
Br J Haematol
; 157(5): 564-79, 2012 Jun.
Artigo
Inglês
| MEDLINE | ID: mdl-22428569
12.
What issues matter most to people with multiple myeloma and how well are we measuring them? A systematic review of quality of life tools.
Eur J Haematol
; 89(6): 437-57, 2012 Dec.
Artigo
Inglês
| MEDLINE | ID: mdl-22985406
13.
The addition of cyclophosphamide to lenalidomide and dexamethasone in multiply relapsed/refractory myeloma patients; a phase I/II study.
Br J Haematol
; 150(3): 326-33, 2010 Aug.
Artigo
Inglês
| MEDLINE | ID: mdl-20553268
14.
Health-related quality of life from the MM-003 trial of pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone in relapsed and/or refractory multiple myeloma.
Haematologica
; 100(2): e63-7, 2015 Feb.
Artigo
Inglês
| MEDLINE | ID: mdl-25425684
15.
International evidence-based consensus diagnostic and treatment guidelines for unicentric Castleman disease.
Blood Adv
; 4(23): 6039-6050, 2020 12 08.
Artigo
Inglês
| MEDLINE | ID: mdl-33284946
16.
Alternate day pomalidomide retains anti-myeloma effect with reduced adverse events and evidence of in vivo immunomodulation.
Br J Haematol
; 141(1): 41-51, 2008 Apr.
Artigo
Inglês
| MEDLINE | ID: mdl-18324965
17.
Rituximab and thalidomide combination therapy for Castleman disease.
Br J Haematol
; 158(3): 421-3, 2012 Aug.
Artigo
Inglês
| MEDLINE | ID: mdl-22583139
18.
Bortezomib, Bendamustine and Dexamethasone vs Thalidomide, Bendamustine and Dexamethasone in Myeloma patients presenting with renal failure (OPTIMAL): a randomised, multi-centre phase II trial.
Blood Cancer J
; 12(11): 162, 2022 11 29.
Artigo
Inglês
| MEDLINE | ID: mdl-36446771
19.
Bendamustine in combination with thalidomide and dexamethasone is an effective therapy for myeloma patients with end stage renal disease.
Br J Haematol
; 155(5): 632-4, 2011 Dec.
Artigo
Inglês
| MEDLINE | ID: mdl-21689088
20.
The neutropenia induced by the thalidomide analogue CC-4047 in patients with multiple myeloma is associated with an increased percentage of neutrophils bearing CD64.
Int Immunopharmacol
; 6(7): 1194-203, 2006 Jul.
Artigo
Inglês
| MEDLINE | ID: mdl-16714224